Suppr超能文献

按美国国立卫生研究院 1990 年标准诊断的多囊卵巢综合征患者高雄激素血症的发生率。

Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria.

机构信息

Department of Obstetrics and Gynecology, the David Geffen School of Medicine at UCLA, Los Angeles, California, USA.

出版信息

Fertil Steril. 2010 Apr;93(6):1938-41. doi: 10.1016/j.fertnstert.2008.12.138. Epub 2009 Feb 26.

Abstract

OBJECTIVE

To determine the prevalence of elevated total and free T, and DHEAS, alone and in combination, in patients with polycystic ovary syndrome (PCOS).

DESIGN

Cross-sectional analysis.

SETTING

Tertiary care academic medical center.

PATIENT(S): Seven hundred twenty patients diagnosed with PCOS according to the National Institutes of Health 1990 criteria.

INTERVENTION(S): History, physical examination, and blood sampling.

MAIN OUTCOME MEASURE(S): Hyperandrogenemia, defined as at least one androgen value above the 95th percentile of 98 healthy control women (i.e., total T >88 ng/dL, free T >0.75 ng/dL, and DHEAS >2,750 ng/mL).

RESULT(S): A total of 716 subjects with PCOS were included. The overall prevalence of hyperandrogenemia in PCOS was 75.3%. Supranormal levels of free T were present in 57.6%, of total T in 33.0%, and of DHEAS in 32.7% of patients with PCOS. When assessing the prevalence of two abnormal values, the prevalence of simultaneously elevated androgens was lowest with total T and DHEAS (1.7%) and highest with total T and free T (20.4%). Altogether, simultaneous elevations in all three markers were found in 8.7% of subjects with PCOS.

CONCLUSION(S): Approximately three-fourths of patients with PCOS diagnosed by the National Institutes of Health 1990 criteria have evidence of hyperandrogenemia; the single most predictive assay was the measurement of free T with approximately 60% of patients demonstrating supranormal levels.

摘要

目的

确定多囊卵巢综合征(PCOS)患者中总睾酮和游离睾酮以及 DHEAS 单独和联合升高的患病率。

设计

横断面分析。

地点

三级保健学术医疗中心。

患者

根据美国国立卫生研究院 1990 年标准诊断为 PCOS 的 720 例患者。

干预

病史、体格检查和血液采样。

主要观察指标

高雄激素血症,定义为至少有一种雄激素值高于 98 名健康对照女性的第 95 百分位数(即总睾酮>88ng/dL、游离睾酮>0.75ng/dL 和 DHEAS>2750ng/mL)。

结果

共纳入 716 例 PCOS 患者。PCOS 患者高雄激素血症的总体患病率为 75.3%。游离睾酮水平升高占 57.6%,总睾酮水平升高占 33.0%,DHEAS 水平升高占 32.7%。在评估两种异常值的患病率时,同时存在升高的雄激素的患病率以总睾酮和游离睾酮最低(1.7%),以总睾酮和游离睾酮最高(20.4%)。总共有 8.7%的 PCOS 患者同时存在三种标志物的升高。

结论

根据美国国立卫生研究院 1990 年标准诊断的 PCOS 患者中,约有四分之三存在高雄激素血症证据;最具预测性的单一检测是游离睾酮的测量,约有 60%的患者表现出高于正常水平。

相似文献

1
Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria.
Fertil Steril. 2010 Apr;93(6):1938-41. doi: 10.1016/j.fertnstert.2008.12.138. Epub 2009 Feb 26.
3
Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome.
Fertil Steril. 2012 Nov;98(5):1318-25.e1. doi: 10.1016/j.fertnstert.2012.07.1057. Epub 2012 Jul 24.
4
Menstrual dysfunction in polycystic ovary syndrome: association with dynamic state insulin resistance rather than hyperandrogenism.
Fertil Steril. 2021 Jun;115(6):1557-1568. doi: 10.1016/j.fertnstert.2020.12.015. Epub 2021 Feb 15.
6
Hyperandrogenemia is implicated in both the metabolic and reproductive morbidities of polycystic ovary syndrome.
Fertil Steril. 2014 Mar;101(3):840-5. doi: 10.1016/j.fertnstert.2013.11.027. Epub 2014 Jan 11.
7
Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS).
Clin Endocrinol (Oxf). 2005 Jun;62(6):644-9. doi: 10.1111/j.1365-2265.2005.02256.x.
8
Minimal difference in phenotype between adolescents and young adults with polycystic ovary syndrome.
Fertil Steril. 2019 Feb;111(2):389-396. doi: 10.1016/j.fertnstert.2018.10.020. Epub 2018 Dec 7.
9
Prevalence and impact of hyperandrogenemia in 1,218 women with polycystic ovary syndrome.
Endocrine. 2014 Nov;47(2):631-8. doi: 10.1007/s12020-014-0200-7. Epub 2014 Apr 22.

引用本文的文献

2
Adropin ameliorates reproductive dysfunctions in letrozole-induced PCOS mouse.
Sci Rep. 2025 Mar 13;15(1):8659. doi: 10.1038/s41598-025-93215-x.
4
Androgens and Hirsutism in a Large Cohort of Portuguese Women.
J Clin Med. 2025 Jan 21;14(3):673. doi: 10.3390/jcm14030673.
5
Approach to the Patient: Diagnostic Challenges in the Workup for Polycystic Ovary Syndrome.
J Clin Endocrinol Metab. 2025 Jun 17;110(7):e2298-e2308. doi: 10.1210/clinem/dgae910.
6
Polycystic ovary syndrome as a metabolic disease.
Nat Rev Endocrinol. 2025 Apr;21(4):230-244. doi: 10.1038/s41574-024-01057-w. Epub 2024 Nov 28.
7
Signs of Potential Androgen Excess Across the Lifespan in a US-based Digital Cohort Study.
J Clin Endocrinol Metab. 2025 May 19;110(6):1667-1679. doi: 10.1210/clinem/dgae674.
9
Metabolic characteristics of different phenotypes in reproductive-aged women with polycystic ovary syndrome.
Front Endocrinol (Lausanne). 2024 Jul 23;15:1370578. doi: 10.3389/fendo.2024.1370578. eCollection 2024.

本文引用的文献

2
The diagnosis of polycystic ovary syndrome: the criteria are insufficiently robust for clinical research.
Clin Endocrinol (Oxf). 2007 Dec;67(6):811-5. doi: 10.1111/j.1365-2265.2007.02932.x. Epub 2007 Aug 29.
3
Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement.
J Clin Endocrinol Metab. 2007 Feb;92(2):405-13. doi: 10.1210/jc.2006-1864. Epub 2006 Nov 7.
6
Ferriman Gallwey self-scoring I: performance assessment in women with polycystic ovary syndrome.
J Clin Endocrinol Metab. 2005 Jul;90(7):4112-4. doi: 10.1210/jc.2004-2243. Epub 2005 Apr 12.
8
Androgen excess in women: experience with over 1000 consecutive patients.
J Clin Endocrinol Metab. 2004 Feb;89(2):453-62. doi: 10.1210/jc.2003-031122.
9
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.
Fertil Steril. 2004 Jan;81(1):19-25. doi: 10.1016/j.fertnstert.2003.10.004.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验